share_log

CRISPR Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144

CRISPR Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144

CRISPR Therapeutics | 144:拟议出售证券
SEC announcement ·  04/15 16:29
Moomoo AI 已提取核心信息
CRISPR Therapeutics AG officer and director Samarth Kulkarni is set to sell 19,582 common shares on April 15, 2024, with an aggregate market value of approximately $1.17 million. The shares to be sold were acquired on the same date through a stock option exercise, with the securities obtained directly from the issuer and paid for in cash. Over the past three months, Kulkarni has sold a total of 130,755 shares of CRISPR Therapeutics, generating gross proceeds of nearly $8.95 million.
CRISPR Therapeutics AG officer and director Samarth Kulkarni is set to sell 19,582 common shares on April 15, 2024, with an aggregate market value of approximately $1.17 million. The shares to be sold were acquired on the same date through a stock option exercise, with the securities obtained directly from the issuer and paid for in cash. Over the past three months, Kulkarni has sold a total of 130,755 shares of CRISPR Therapeutics, generating gross proceeds of nearly $8.95 million.
CRISPR Therapeutics AG高管兼董事萨玛斯·库尔卡尼定于2024年4月15日出售19,582股普通股,总市值约为117万美元。待售股票于同日通过股票期权行使收购,证券直接从发行人处获得并以现金支付。在过去的三个月中,库尔卡尼共出售了CRISPR Therapeutics的130,755股股票,总收益接近895万美元。
CRISPR Therapeutics AG高管兼董事萨玛斯·库尔卡尼定于2024年4月15日出售19,582股普通股,总市值约为117万美元。待售股票于同日通过股票期权行使收购,证券直接从发行人处获得并以现金支付。在过去的三个月中,库尔卡尼共出售了CRISPR Therapeutics的130,755股股票,总收益接近895万美元。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息